Navigation Links
Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
Date:11/19/2013

SEATTLE, Nov. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302 is the company's proprietary Pharmacosurgery® product being developed for all ILR, including cataract surgery and refractive lens exchange.

The analyses were presented by Steve Whitaker, M.D., Omeros' vice president of clinical development and chief medical officer on November 17 at the Annual American Academy of Ophthalmology (AAO) Meeting in New Orleans. The clinical data presented at the AAO meeting and shown below demonstrated that, in these clinical trials in which all patients received standard-of-care preoperative mydriatic topical drops, OMS302 reduced the occurrence of intraoperative pupil constriction. Intraoperative miosis is an important risk factor for surgical complications. As shown in the figure below, pupil constriction of at least 3 millimeters was common in control patients while constriction greater than 1 millimeter was uncommon in OMS302-treated patients.

(Photo: http://photos.prnewswire.com/prnh/20131119/MM19781 )

"We are pleased with the recognition that the recent clinical data for OMS302 received from the ophthalmic community during the AAO annual meetings," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Ophthalmologists continue to appreciate the potential clinical benefits of OMS302, and we look forward to the drug's expected commercial launch in 2014."

About Omeros' OMS302 Program
OMS302 is Omeros' product being developed for use du
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... and LONDON , August 26, 2014 ... FDNA Inc. ( http://www.fdna.com ) and London Medical Databases ... partnered to offer, for the first time, online access ... FDNA, developer of the Facial Dysmorphology ... collection into Face2Gene [ TM ] , ...
(Date:8/26/2014)... SAN DIEGO , Aug. 26, 2014   ... M.D., has been named vice president, clinical development, and ... president, clinical operations. "As we advance ... we are expanding our clinical team with individuals who ... and commercialization activities," said Jamey Skillings , M.D., ...
(Date:8/26/2014)... , Aug. 26, 2014  Zimmer Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2014. The cash dividend of ... 31, 2014, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
Breaking Medicine Technology:FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 2FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 3Tocagen Expands Clinical Development Team; 2Tocagen Expands Clinical Development Team; 3
... N.J., July 26, 2011 Watson Pharmaceuticals, Inc. ... definitive agreement to acquire a portfolio of generic ... result of the merger between Perrigo Company and ... including four FDA-approved products and two undisclosed development-stage ...
... N.J., July 26, 2011 The Board of Directors of ... a leading global medical technology company, today announced that, in ... A. Forlenza as Chief Executive Officer and President, effective October ... the Board at that time. Also effective October 1, current ...
Cached Medicine Technology:Watson Enters into Agreement to Acquire Products Related to Perrigo's Acquisition of Paddock Laboratories 2BD Board of Directors Elects Vincent A. Forlenza as Next Chief Executive Officer, Effective October 1, 2011 2BD Board of Directors Elects Vincent A. Forlenza as Next Chief Executive Officer, Effective October 1, 2011 3
(Date:8/27/2014)... Crossing, PA (PRWEB) August 27, 2014 Time ... successfully launched its first-ever golf event! , With 80-degree ... for the Time To Play Golf (TTPGolf) Inaugural Outing. Around ... August 4th event, staged at the beautiful Heron Glen Golf ... with a bang and everyone seemed to be having a ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 PCOS (Polycystic ... and puts them at risk for a number of ... widely known or well understood even within the medical ... excess body hair (hirsutism) and excess body fat around ... aware that their problems are caused by PCOS. , ...
(Date:8/27/2014)... The Connecticut Community for Addiction Recovery (CCAR) ... 2014, from 10:00 AM – 2:00 PM in Bushnell Park ... participants across the state to show their support for recovery ... state capitol. , Recovery Walks! is a celebration for the ... and other drugs as well as their families, friends, and ...
(Date:8/26/2014)... 2014 Recently, BambooIndustry.com, the popular online ... of bamboo floorings for the online market. ... flooring promotion. All the new items are offered at ... The special offer will end on September 10, 2014. ... floorings are provided with low shipping costs. The company ...
(Date:8/26/2014)... (PRWEB) August 27, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... without medication. , “While many people need medication to ... withdrawal symptoms and fighting relapse triggers like anxiety and ...
Breaking Medicine News(10 mins):Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 3Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 4Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 5Health News:The CT Community for Addiction Recovery to Proudly Host 15th Annual Recovery Walks! 2Health News:Discounted, High Quality Bamboo Floorings Provided Online By BambooIndustry.com 2Health News:Latest Best Drug Rehabilitation Blog Post Looks at 6 Ways to Beat Addiction with Medication 2Health News:Latest Best Drug Rehabilitation Blog Post Looks at 6 Ways to Beat Addiction with Medication 3
... the AIDS drug Retrovir (AZT). This generic drug// is manufactured ... be able to market this anti-retroviral drug in US, but ... it will be made available for purchase and use abroad ... emergency plan for AIDS relief was announced in 2003, by ...
... sectional study across Europe, researchers have reported// that there ... the parents and their socio-economic status with the condition ... carried across the countries of Denmark, Estonia, and Portugal, ... Journal (BMJ). ,Across Europe, children from poor families ...
... Gengraine Technologies (Avesthagen) of India is collaborating// with ... Developing Countries (IFU) of Germany for Osteoporosis research. ... euro. Avesthagen said “"The alliance will cover diagnosis, ... disorders.” The research studies related to menopause linked ...
... Technologists annual meeting in US// have warned the general people ... these are illnesses that can threaten the health of the ... ,The studies presented at the meeting said that often people ... illnesses. A healthy adult is less likely to contract a ...
... the research carried out so far into the effects// of ... a new phase III trial is scheduled to commence this ... escalated, causing soaring prices and reports of fake products entering ... been triggered by the publication of Shults’ earlier phase II ...
... (albumin is major part// the protein spectrum in the body) ... study. A simple, inexpensive test for urinary albumin may help ... deliver early. ,A study was released in the American ... Kidney Foundation) this month that suggests this test. "Research ...
Cached Medicine News:Health News:Education And Income Level May Not Guarantee Health 2Health News:Scientists Warn Against Food Borne Illnesses 2Health News:New Study to look at the Beneficial Effects of Coenzyme Q10 on Parkinson’s disease 2Health News:Premature Babies More Likely If Women Have Higher Protein Albumin In Urine 2
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Ident-A-Drug gives you quick accurate identification of oral tablets and capsules used in North America....
... latest in scientific clinical trial activity and ... resources from CenterWatch. This highly valuable resource ... and stay abreast of medical breakthroughs on ... Trials, Clinical Trial Results, Newly Approved Drugs, ...
Providing patients and their advocates with a variety of information services and educational materials on clinical research....
Medicine Products: